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The role of vitamin D in left ventricular hypertrophy and car-
diac function. Cardiovascular disease is the leading cause of
death among patients with end-stage renal disease (ESRD).
Traditional cardiac risk factors, as well as other factors specific
to the ESRD population such as hyperphosphatemia, elevated
calcium and phosphate product, abnormal lipid metabolism, hy-
perhomocysteinemia, and chronic inflammation play a role in
the excessive risk of cardiovascular death in this population.
Left ventricular disorders are proven risk factors for cardiac
mortality in hemodialysis patients. These disorders are present
in incident ESRD patients at rates far above the general popu-
lation. There is an accumulating body of evidence that suggests
that vitamin D plays a role in cardiovascular disease. Abnormal
vitamin metabolism, through deficiency of the active form of
1,25-dihydroxyvitamin D3, and acquired vitamin D resistance
through the uremic state, have been shown to be important in
ESRD. Vitamin D deficiency has long been known to affect car-
diac contractility, vascular tone, cardiac collagen content, and
cardiac tissue maturation. Recent studies using vitamin D re-
ceptor deficient mice as a model demonstrate a crucial role of
vitamin D in regulation of the renin-angiotensin system. Addi-
tionally, there is emerging evidence linking treatment with vita-
min D to improved survival on hemodialysis and improvement
in cardiac function. The emergence of this data is focusing at-
tention on the previously underappreciated nonmineral home-
ostatic effects of vitamin D that very likely play an important
role in the pathogenesis of cardiac disease in ESRD.
Cardiovascular disease is the leading cause of death
among patients with end-stage renal disease (ESRD) [1].
The excessive risk of cardiovascular death in this pop-
ulation can be attributed to the presence of traditional
cardiac risk factors, as well as other factors specific to
the ESRD population such as hyperphosphatemia, el-
evated calcium and phosphate product, abnormal lipid
metabolism, hyperhomocysteinemia, and chronic inflam-
mation [2–8]. Left ventricular disorders play a prominent
role in cardiac risk among hemodialysis patients, with
congestive heart failure conferring an even higher risk
of cardiac mortality than the presence of coronary artery
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disease [9]. Left ventricular hypertrophy (LVH) and left
ventricular systolic function have both been shown to
be independent risk factors for cardiovascular mortal-
ity in ESRD patients [10, 11], and are present in incident
ESRD patients at rates far above the general population
[9]. The pathophysiology of LVH in the ESRD popu-
lation is not known exactly, but factors that have been
implicated include hypertension, anemia, and chronic
volume overload [12]. There is an accumulating body of
evidence that suggests that vitamin D plays a role in car-
diovascular disease. Abnormal vitamin metabolism has
long been known to be important in the pathogenesis
of secondary hyperparathyroidism through deficiency of
the active form of 1,25-dihydroxyvitamin D3 [13] and ac-
quired vitamin D resistance through the uremic state [14,
15], but only recently has attention focused on vitamin D
metabolism and cardiac disease in ESRD. Much of the
evidence linking vitamin D to cardiac disease has been
available for quite some time, but the importance of it is
becoming clearer as the molecular mechanisms of vitamin
D’s actions in the cardiovascular system are elucidated,
and the results of recent studies in the area of treatment
with vitamin D analogues become available.
LEFT VENTRICULAR HYPERTROPHY AND
CONGESTIVE HEART FAILURE IN RENAL
FAILURE
The burden of cardiovascular disease is well known
in the ESRD population, with cardiovascular disease,
including myocardial infarction (MI), congestive heart
failure, and sudden cardiac death accounting for 50% of
deaths among ESRD patients [1]. After stratification by
age, gender, race, and presence of diabetes, the cardiovas-
cular mortality of ESRD patients undergoing hemodial-
ysis or peritoneal dialysis is 10 to 20 times higher than
the general population [12]. The pathogenesis of car-
diac disease in the ESRD population is complex, but in-
volves the interplay of traditional risk factors along with
risk factors that are specific to the dialysis population.
The novel risk factors among dialysis patients include
hyperphosphatemia, elevated calcium and phosphate
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Table 1. Summary of human studies linking vitamin D with hypertension and cardiovascular disease
Author Findings Model Reference
Baksi Increased contractility of cardiac tissue in response to increased
extracellular calcium
[48]
Weishaar Increased plasma renin activity [32]
Increased contractility of isolated aortic rings in response to norepinephrine [32]
Increased collagen in cardiac tissue Vitamin D–deficient rats [50]
O’Connell Shift in myosin side chain favoring V1 isotype [53]
Walters Vitamin D3 stimulates uptake of calcium by cardiac tissue [51]
O’Connell 1,25-dihydroxyvitamin D3 reduces cellular proliferation of cultured
myocytes by decreasing entry into S-phase
Cultured myocytes [52]
O’Connell 1,25-dihydroxyvitamin D3 inhibits cardiac myocyte differentiation through
protein kinase C dependent mechanism
[56]
Li Elevated angiotensin II, aldosterone, hypertension, and increased heart mass Vitamin D receptor deficient mice [31]
Elevated intracardiac renin [58]
product, lipoprotein(a), hyperhomocysteinemia, and
chronic inflammation [2–8]. These risk factors are most
closely associated with atherogenesis, though the pres-
ence of LV dysfunction is another important predictor of
cardiac death on dialysis [10, 11].
The impact of congestive heart failure on survival in
ESRD patients on dialysis is striking. The presence of
congestive heart failure (CHF) confers a higher adjusted
relative risk of death (1.26 vs. 1.11) than does the pres-
ence of coronary artery disease in new ESRD patients [9].
Harnett et al reported an unadjusted 5-year survival of
20% among patients who initiate hemodialysis with con-
gestive heart failure compared with a 50% survival among
those without heart failure [16]. Similar findings were re-
ported by Silberberg from a cohort of 91 patients who had
an echocardiogram within 2 months of starting hemodial-
ysis. In patients with a left ventricular mass index (LVMI)
>125, 5-year survival was slightly above 20% and, among
those with an LVMI <125, 5-year survival was 50%. In-
terestingly, Foley et al [17] found that the presence of
coronary artery disease was not predictive of mortality on
hemodialysis when age, diabetes, angina pectoris, cardiac
failure, and serum albumin were analyzed as covariates.
However, the presence of clinical heart failure and the
presence of systolic dysfunction were predictive of poor
long-term survival, with no patients with either of these
abnormalities surviving to 5 years [18]. This could be re-
flective of the 6-month survival requirement of study en-
try as early mortality has been shown to be predicted by
the presence of coronary artery disease [19]. However,
it also suggests that much of the mortality of coronary
artery disease in dialysis patients is manifest through car-
diac failure [20].
The presence of left ventricular hypertrophy is an im-
portant risk factor in the development of congestive heart
failure in hemodialysis. Left ventricular disorders are very
common on hemodialysis. Parfrey et al reported that only
15.6% of patients begin dialysis therapy with a normal
echocardiogram, with concentric LVH, LV dilatation, and
systolic dysfunction occurring in 40.7%, 28%, and 15.6%,
respectively [10]. In a cross-sectional study of chronic kid-
ney disease and dialysis patients, Greaves et al found
a high prevalence of echocardiographic LVH or LV di-
latation to occur in 50% of patients [21]. The presence
of these individual LV disorders was significantly associ-
ated with the subsequent development of clinical CHF
while on dialysis. In Harnett’s study, higher LV mass in-
dex and increased LV end diastolic diameter were asso-
ciated with subsequent development of CHF [16]. Thus,
addressing left ventricular disorders should be taken on
with the same urgency in ESRD patients as atherosclero-
sis risk factor reduction. Modalities that have been shown
to reduce LVH in renal failure include treatment with
angiotensin-converting enzyme (ACE) inhibitors [22],
control of anemia [23], and daily dialysis [24]. Now, re-
cent evidence is emerging that vitamin D therapy plays
an independent role in treatment of increased LV mass.
The evidence for an emerging role of vitamin D in left
ventricular disorders in renal disease is the topic of the
remainder of this review.
VITAMIN D IN CARDIOVASCULAR DISEASE
There is ample clinical evidence, outside of renal fail-
ure, that vitamin D may a play a role in cardiovascu-
lar disease. Vitamin D deficiency is a common clinical
entity [25], and the association of vitamin D deficiency
and hypertension has been studied on an epidemiologic
level. Serum calcitriol levels are inversely related to
blood pressure in normo- and hypertensive subjects [26,
27]. Additionally, there are earlier interventional stud-
ies, looking at the effects of vitamin D supplementation
and blood pressure in normotensives and hypertensives.
In 7 studies reviewed by Zitterman, 3 found no effect,
and 4 found lower blood pressures in healthy individu-
als treated with 25-hydroxyvitamin D3 supplementation
[28]. Hypocalcemia is a potential explanation for these
findings [29, 30], although another plausible mechanism
for the association of vitamin D deficiency and hyperten-
sion is hyper-reninemic hyperaldosteronism, as has been
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Table 2. Summary of animal studies demonstrating cardiovascular effects of vitamin D
Author(s) Finding Study population Reference
Kristal-Boneh/Young Serum calcitriol levels are inversely related to
blood pressure
Normal and hypertensive, population-based study [26, 27]
Zitterman Possible lower BP in healthy individuals taking
Vitamin D supplementation
Review of 7 intervention studies [28]
Low calcitriol, lower calcium, and higher
phosphorus levels are associated with
congestive heart failure
CHF population with creat <2.0 mg/dL [33]
Park Regression of LV hypertrophy in patients
treated with vitamin D
Hemodialysis patients, small study [35]
Mizani Normalization of LV hypertrophy in patients
treated with high doses of paricalcitol
Hemodialysis patients, small study [34]
Teng Decreased cardiovascular mortality in patients
treated with paricalcitol
Large studies, epidemiologic, cross-sectional [37, 38]
demonstrated in vitamin D receptor knockout mice [31]
and vitamin D–deficient animals [32]. Additionally, vita-
min D deficiency has also been implicated in the patho-
genesis of CHF in patients without renal failure. Low
levels of calcitriol, lower serum calcium, and higher phos-
phorus levels are associated with clinical congestive heart
failure and elevated pro-ANP levels in patients with a
serum creatinine <2 mg/dL [33]. However, the most di-
rect evidence for the role of vitamin D in cardiac disease
comes from studies in ESRD patients receiving vitamin
D analogues for the control of hyperparathyroidism. Pre-
liminary data from our group show short daily hemodial-
ysis reduces left ventricular mass, and that treatment with
paricalcitol may have an additive effect [34]. This is con-
sistent with the results of Park et al, who showed regres-
sion of LV hypertrophy in hemodialysis patients treated
with vitamin D [35]. There is also emerging evidence that
treatment with vitamin D analogues reduces mortality in
hemodialysis patients [36–38]. It is too early to know if
the beneficial effect of vitamin D treatment is mediated
by effects on cardiac function; there is, however, litera-
ture to support the notion that vitamin D has a beneficial
effect on cardiac tissue.
MOLECULAR BASIS OF VITAMIN D
PHYSIOLOGY IN CARDIAC FUNCTION
The vitamin D receptor has a wide tissue distribution,
including cardiac tissue [39], and clearly, vitamin D plays
important roles beyond its effects on calcium and phos-
phorus homeostasis. Vitamin D exerts its effects on tis-
sues through interaction with the vitamin D receptor
(VDR). The VDR is a member of the nuclear recep-
tor family that activates gene transcription once bound
by ligand [40]. Like other members of this family, VDR
forms a heterodimer with the RXR (retinoic acid) recep-
tor in order to bind DNA. The active form of vitamin D,
1,25-dihydroxyvitamin D3, binds to the VDR with much
higher affinity than 25-hydroxyvitamin D3 [41]. There are
many novel activities of vitamin D that are beginning to
be recognized. These include effects on immune function,
cellular proliferation, and neuroprotection [42–45]. Thus,
it is clear that in the uremic state, which is associated with
vitamin D deficiency [13] and vitamin D resistance [14,
15], many tissues can be affected by abnormal vitamin D
physiology, including cardiac tissue.
Vitamin D has been shown to have several biological
effects on the heart in animal studies. It plays a role in
cardiac cell contraction, proliferation, maturation, pro-
tein expression, and collagen expression. The VDR was
first identified in cultured cardiac cells by Sampson et
al [46], and in rat normal hearts by Walters et al [47].
Baksi et al showed increased contractility in response to
increasing concentration of the extracellular calcium bath
in atria from rats maintained on a vitamin D–deficient
diet [48]. Additionally, there is increased contractile re-
sponse to norepinephrine in insolated aortic rings from
vitamin D–deficient mice, as well as increased plasma
renin activity [32]. These results suggest that vitamin D
may play a role in maintenance of vascular tone and car-
diac output; given the association of hypertension and
hypocalcemia in humans [49], these could not be at-
tributed to vitamin D depletion alone. To address this, the
rats were maintained on a diet containing 2.5% calcium
and 1.0% phosphate, a change in diet that normalizes
PTH, calcium, and phosphorus in the vitamin D–deficient
animals. With normalization of these parameters, the con-
tractile response of isolated atria and increased renin
levels remained; however, the vascular smooth muscle
response to norepinephrine was abolished. The implica-
tion is that there are indirect and direct effects of vitamin
D on cardiovascular function, and that the one mecha-
nism of indirect action is through calcium concentration.
Additionally, Weishaar has shown that rats fed a vitamin
D–deficient diet have increased amounts of collagen by
measuring hydroxyproline per gram of heart tissue and
collagen deposition in the extracellular space of the my-
ocardium. This effect could not be suppressed by normo-
calcemia when the animals were fed a 2.5% calcium diet
[50], suggesting that this is a direct effect of vitamin D
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Fig. 1. Mechanisms of effects of 1,25 dihydroxyvitamin D3 on cardiac function and left ventricular hypertrophy.
deficiency. Thus, vitamin D deficiency appears to favor a
hyperreninemic, hypertensive state with impairment of
cardiac contractile function and an increase in myocar-
dial collagen content, a series of abnormalities that could
predispose to LVH and CHF.
Vitamin D also has many effects on cardiac tissue
growth and development. Walters et al demonstrated that
the uptake of calcium by cardiac muscles cells is in part
regulated by vitamin D3, an effect that is receptor medi-
ated, requiring transcription and protein synthesis [51].
Vitamin D has also been shown to affect the growth of
cardiac cells in culture. O’Connell et al showed that 1,25-
dihydroxyvitamin D3 reduces proliferation rate, PCNA
levels, and c-myc levels of myocytes in culture through
decreased entry into S-phase [52]. Vitamin D deficiency
also results in a shift in the tissue distribution of V1 and
V3 myosin chains, favoring the V1 isotype [53]. Shifts in
myosin isotypes have been shown to alter myocyte con-
tractility [54, 55]. Interestingly, this shift was seen only if
the animals were maintained with normocalcemia (2.5%
calcium and 1.0% phosphorus diet); thus, increased car-
diac contractility cannot be completely explained by shift
in myosin distribution [53]. Cardiac myocyte differentia-
tion is also inhibited by 1,25-dihydroxyvitamin D3. This
is evidenced by inhibition of the increase in MM (cardiac
specific) creatinine kinase (CK) isotype from the predom-
inant BB (brain specific) CK isotype found in immature
myocytes. This effect of vitamin D on cardiac myocyte
differentiation can be inhibited by staurosporine, and
mimicked by PMA (phorbol 12-myrsitate 13-aceteate),
demonstrating that this effect of vitamin D is mediated
by protein kinase C activation [56]. It is clear that vitamin
D plays a crucial role in cardiac tissue through regulation
of intracellular calcium levels, proliferation, cell differen-
tiation, and maturation.
Li et al have recently characterized the VDR-deficient
mice, and have demonstrated the effects of vitamin D
on the renin-angiotensin system [31]. They showed that
VDR-deficient mice have elevated levels of circulating
angiotensin II (Ang II), increased production of renin
with hypertension (readily reversed by captopril), and in-
creased heart mass. They also showed that administration
of vitamin D suppressed renin expression in normal mice.
The effects on renin secretion and Ang II levels were
not abrogated by dietary normalization of the serum cal-
cium. This is consistent with the alterations in the renin-
angiotensin axis described by Weishaar 12 years earlier in
vitamin D–deficient animals [32]. The increased renin ex-
pression in VDR receptor mice was suppressible by salt
loading, but renin levels remained much higher than in
the control mice, suggesting that 1,25-dihydroxyvitamin
D3 has an independent, but additive, effect with distal
salt delivery on regulation of renin secretion and blood
pressure regulation. The direct applicability of this animal
data to the human situation is unclear at the present time,
but the VDR has been identified in human heart tissue as
a 55 kD protein [57]. Given the clinical literature that is
increasingly implicating vitamin D in the pathogenesis of
cardiac disease, especially in dialysis patients, it is likely
that many of the effects of vitamin D on cardiac func-
tion in the rodent models apply to humans. Thus, func-
tional or absolute vitamin D deficiency may predispose to
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development of LVH by impairing cardiac contractility,
increasing myocardial collagen content, altering myosin
protein expression, and activating the renin-angiotensin
axis.
CONCLUSION
Vitamin D has long been part of the nephrologist’s
armamentarium in treating secondary hyperparathy-
roidism. There is now increasing evidence that vitamin
D treatment has more far-reaching consequences in the
dialysis population than just treatment of secondary hy-
perparathyroidism and prevention of renal osteodystro-
phy. Vitamin D plays a role in cardiovascular disorders
such as hypertension and CHF in the general popula-
tion, and there is ample evidence that vitamin D is im-
portant in the development and physiology of cardiac
tissue. Clinical studies have begun to demonstrate some
of the beneficial effects of vitamin D on left ventricular
hypertrophy in patients with ESRD, as well as improved
survival of hemodialysis patients treated with vitamin D.
Given the overwhelming burden of cardiovascular mor-
tality in the ESRD population, and the important role
that left ventricular hypertrophy plays in this mortality,
it is likely that abnormal vitamin D metabolism in renal
failure contributes to cardiovascular disease. This can oc-
cur through deficiency of the 1,25-dihydroxyvitamin D3
or through resistance to its actions in the uremic state.
Regardless of the mechanism, further study in this area
is needed through a prospective, randomized trial specif-
ically looking at cardiovascular and mortality outcomes
in a hemodialysis and CKD populations. Design of such
studies will have to carefully account for differences in
calcium phosphate product, hyperparathyroidism, and
phosphate control between study and control groups in
order to determine the direct effects of vitamin D.
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